Clinical Trials
41 trialsNCT04832854 2026-03-11
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT05733611 2026-02-02
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
Replimune, Inc.
Phase 2 Terminated
NCT05746481 2026-01-22
Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
University of Pittsburgh
Phase 2 Terminated
NCT04770272 2026-01-12
neoMono
Palleos Healthcare GmbH
Phase 2 Terminated
NCT04276376 2025-12-01
ARIANES
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT05180006 2025-12-01
BIS-Program
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT04549428 2025-11-18
Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC
Oncology Institute of Southern Switzerland
Phase 2 Terminated
NCT04373369 2025-11-03
Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Washington University School of Medicine
Phase 2 Terminated
NCT02982694 2025-10-01
Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer
Vall d'Hebron Institute of Oncology
Phase 2 Terminated
NCT05537402 2025-09-24
LOST-B
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT05448677 2025-04-20
ABE-LIVER
University Hospital, Grenoble
Phase 2 Terminated
NCT04512430 2025-04-02
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
Fundación GECP
Phase 2 Terminated
NCT04322643 2025-02-25
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT05776875 2025-01-15
Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC
Yale University
Phase 2 Terminated
NCT03272217 2025-01-07
Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer
Hoosier Cancer Research Network
Phase 2 Terminated
NCT04923776 2024-12-30
Liver Directed RT + Chemo-immunotherapy for ES-SCLC
Columbia University
Phase 2 Terminated
NCT04933227 2024-11-14
A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
Hoffmann-La Roche
Phase 2 Terminated
NCT04541173 2024-06-05
Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Hoosier Cancer Research Network
Phase 2 Terminated
NCT04610684 2024-03-13
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03357224 2024-02-22
PARCT
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT05060003 2024-02-20
Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection
Washington University School of Medicine
Phase 2 Terminated
NCT04099836 2023-12-26
Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib
Duke University
Phase 2 Terminated
NCT04690855 2023-12-04
TARA
Hoosier Cancer Research Network
Phase 2 Terminated
NCT04308785 2023-10-23
A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT03737123 2023-09-13
Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT05110781 2023-09-05
Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site
University of California, Davis
Phase 2 Terminated
NCT02322814 2023-04-13
A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread
Hoffmann-La Roche
Phase 2 Terminated
NCT03713944 2023-03-01
Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
Big Ten Cancer Research Consortium
Phase 2 Terminated
NCT03386721 2023-02-21
Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
Phase 2 Terminated
NCT03422523 2022-08-22
ARGO
University Hospital Southampton NHS Foundation Trust
Phase 2 Terminated
NCT03147040 2022-07-19
GELATO
The Netherlands Cancer Institute
Phase 2 Terminated
NCT03050060 2022-06-22
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
University of Washington
Phase 2 Terminated
NCT03894007 2021-09-23
PREDIXIIHER2
Karolinska University Hospital
Phase 2 Terminated
NCT03115801 2021-09-22
A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers
Weill Medical College of Cornell University
Phase 2 Terminated
NCT03952325 2021-07-30
CONTESSA TRIO
Odonate Therapeutics, Inc.
Phase 2 Terminated
NCT03644823 2021-03-30
COM-IT-1
Oslo University Hospital
Phase 2 Terminated
NCT02303951 2021-02-03
NEO-VC
University Hospital Tuebingen
Phase 2 Terminated
NCT03465891 2021-01-12
Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT02609984 2020-07-07
IMDZ-C232
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Terminated
NCT03120676 2019-11-14
Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT03029832 2019-05-31
A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy
Genentech, Inc.
Phase 2 Terminated